News and Stories

CBD Epilepsy Blog

The interest in cannabis-based products for the treatment of refractory epilepsy has skyrocketed in recent years. Cannabis products with high content in THC, utilized primarily for recreational purposes, are generally unsuitable for this indication, primarily because THC is associated with many undesired effects. Compared with THC, cannabidiol (CBD) shows a better defined anticonvulsant profile in animal models and is largely devoid of adverse psychoactive effects and abuse liability. Over the years, this has led to an increasing use of CBD-enriched extracts in seizure disorders, particularly in children. Although improvement in seizure control and other benefits on sleep and behavior have been often reported, interpretation of the data is made difficult by the uncontrolled nature of these observations. Evidence concerning the potential anti-seizure efficacy of cannabinoids reached a turning point in the last 12 months, with the completion of three high-quality placebo-controlled adjunctive- therapy trials of a purified CBD product in patients with Dravet syndrome and Lennox-Gastaut syndrome. In these studies, CBD was found to be superior to placebo in reducing the frequency of convulsive (tonic-clonic, tonic, clonic, and atonic) seizures in patients with Dravet syndrome, and the frequency of drop seizures in patients with Lennox-Gastaut syndrome. For the first time, there is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes. Natures Replies CBD oil has no more that 0.2% THC and so is not only non-psychoactive but is also ideal for assisting in the control of seizures in this condition.

Leave a Reply

Your email address will not be published. Required fields are marked *

en_GBEnglish
es_ESSpanish fr_FRFrench de_DEGerman en_GBEnglish
X